← Leaderboards
Michele Laura Jonsson Funk
University Of North Carolina Chapel Hill
$2,731,519
Attributed
$2,731,519
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $569.5K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$2,078,370 · 2
AHRQ$653,149 · 1
By mechanism
R01$2,078,370 · 2
K02$653,149 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Kevin M Weeks$22,683,080
- Gerhard W Meissner$11,174,054
- Penny Gordon-Larsen$20,495,706
- John H Gilmore$26,231,091
- Angela D Kashuba$21,136,729
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadBaseFaceHealthcareEvidence BaseElderlyClinical ManagementBenefits And RisksDisease OutcomeDrug DevelopmentEffectivenessAttentionEfficacy TestingClinical CareClinical PracticeAmericanAccountingCardiovascular DiseasesCardiovascular Disorder PreventionComparative EffectivenessDatabasesDevicesAdverse EventHeterogeneity
Grant awards (12)
Methods for Estimating Sex Differences in Safety and Effectiveness of Drugs$359,174
R01 · FY2017 · HL · contact PI
Methods for Estimating Sex Differences in Safety and Effectiveness of Drugs$359,174
R01 · FY2016 · HL · contact PI
Methods for Estimating Sex Differences in Safety and Effectiveness of Drugs$391,217
R01 · FY2015 · HL · contact PI
Methods for Estimating Sex Differences in Safety and Effectiveness of Drugs$569,466
R01 · FY2014 · HL · contact PI
Doubly robust elimination: best practices for comparative effectiveness research$138,710
K02 · FY2013 · HS · contact PI
Doubly robust elimination: best practices for comparative effectiveness research$134,579
K02 · FY2012 · HS · contact PI
Doubly robust elimination: best practices for comparative effectiveness research$130,553
K02 · FY2011 · HS · contact PI
Doubly robust elimination: best practices for comparative effectiveness research$126,263
K02 · FY2010 · HS · contact PI
Doubly robust elimination: best practices for comparative effectiveness research$123,044
K02 · FY2009 · HS · contact PI
Effect/Earlier HAART/HIV disease progression/survival$136,497
R01 · FY2007 · AI · contact PI
Effect/Earlier HAART/HIV disease progression/survival$140,669
R01 · FY2006 · AI · contact PI
Effect/Earlier HAART/HIV disease progression/survival$122,173
R01 · FY2005 · AI